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1. Introduction 
Patients with chronic liver disease are characterized by hepatic inflammation and the 
destruction of hepatocytes. Viral antigen-specific cytotoxic T lymphocytes, polyclonal 
cytokines, immune modulators, and oxidized biomolecules have been shown to induce 
damage and destruction of hepatocytes in these patients (Tsutsui et al., 2003). The 
contribution of oxidative stress per se to the chronic inflammatory state has been 
suggested, and consistent evidence has been afforded that both monocyte/macrophage 
activation and a defect in antioxidant systems occur early in the course of chronic liver 
failure and gradually increase with its progression to end-stage liver disease (Kirkham, 
2007; Videla, 2009). Oxidative stress lead to formation of glycoxidation products, 
including advanced glycation endproducts (AGEs - among them Nε-
(carboxymethyl)lysine (CML) is best known), and advanced oxidation protein products 
(AOPPs). AOPPs can be formed in vitro by exposure of serum albumin to hypochlorous 
acid. In vivo, plasma AOPPs are mainly carried by albumin and their concentrations are 
closely correlated with the levels of dityrosine. Within the heterogeneous group of AGEs, 
Nε-(carboxymethyl)lysine has been identified as a major AGEs in vivo (Reddy et al., 1995). 
Plasma concentrations of AGEs (closely correlating with AOPPs levels) increase with 
progression of chronic diseases (Witko-Sarsat et al., 1996; 1998), therefore CML has been 
considered as liver disease-related biomarker for oxidative stress (Sebeková et al., 2002; 
Yagmur et al., 2006). 
The receptor for advanced glycation endproducts (RAGE) is a signal transduction receptor 
that binds both AGEs and AOPPs. RAGE is expressed by various cell types, including 
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monocytes/macrophages, endothelial cells, smooth muscle cells and renal cells (Miyata et 
al., 1994). Advanced glycation endproducts have been found to act as pro-inflammatory 
factors (Sparvero et al., 2009). Nevertheless, AOPPs are believed to be more closely related to 
inflammation (Alderman et al., 2002; Baskol et al., 2006; Fialova et al., 2006; Witko-Sarsat et 
al., 2003; Yazici et al., 2004) than AGEs, whose receptor for advanced glycation endproducts 
participates in AOPPs-mediated signal transduction (Kalousová et al., 2003; 2005). These 
interactions enhance reactive oxygen species formation, with activation of nuclear factor NF-
κB and release of pro-inflammatory cytokines (Bierhaus et al., 2006; Hyogo & Yamagishi, 
2008; Saito & Ishii, 2004). Moreover, the monocyte/macrophage RAGE can be up-regulated 
by tumor necrosis factor-ǂ (TNF-ǂ) (Miyata et al., 1994). Peripheral blood monocytes showed 
activity and elevated expression of TNF-ǂ which correlated with liver disease severity 
(Hanck et al., 2000). The concentrations of advanced oxidation protein products are high in 
liver cirrhosis of various etiologies (Zuwala-Jagiello et al., 2009) and can reflect 
hemodynamic alterations in the liver (Guo et al., 2008). This is accompanied by the activation 
of monocytes and increased expression of TNF-ǂ (Giron-González et al., 2004). High serum 
levels of TNF-ǂ and interleukin-6 (IL-6) have been found in cirrhotic patients with ascites in 
the absence of demonstrable infection (Tilg et al., 1992; Zeni et al., 1993). 
The accumulation of AGEs has been linked to vascular lesions in diabetes, chronic renal 
insufficiency, and atherosclerosis. Activation of NF-κB, mediated by RAGE, promotes 
expression of the cytokines, as well as pro-inflammatory adhesion molecules (Basta et al., 
2002; Bierhaus et al., 1998; Esposito et al., 1989), what may enhance interaction of cirrhotic 
vasculature with circulating monocytes (Cybulsky et al., 1991; Li et al., 1993). Recently, it has 
also been shown that AOPPs activates vascular endothelial cells via RAGE-mediated signals 
(Guo et al., 2008). 
Endothelial activation plays an active role in the modifications of circulatory status of 
cirrhotic patients (Genesca et al., 1999). The circulatory changes are more evident in 
advanced stages of liver cirrhosis, such as those represented by the presence of ascites or 
hepatorenal syndrome (Porcel et al., 2002). We have demonstrated that elevated levels of 
AOPPs modified–albumin (AOPPs-albumin) are related to the severity of liver cirrhosis 
(Zuwala-Jagiello et al., 2009; 2011). The role of AOPPs-albumin in liver cirrhosis and portal 
hypertension has not yet been studied. The effects of pro-inflammatory cytokines on the 
vessels and on liver function would influence the liver cirrhosis, with higher plasma levels 
of AOPPs indicating a poor prognosis. In the present study, plasma levels of AOPPs-
albumin, as well as of Nε (carboxymethyl)lysine modified-albumin (CML-albumin) and pro-
inflammatory cytokines, such as TNF-ǂ and IL-6, have been analyzed in cirrhotic patients 
and were found to be correlated with clinical parameters of liver dysfunction. 
2. Patients and methods 
2.1 Patients 
This study was performed on 129 patients with chronic liver disease admitted to the Clinic 
of Infectious Diseases, Liver Diseases and Acquired Immune Deficiency for evaluation. The 
experimental group consisted of 68 men and 61 women with age of 18–74 years (median age 
was 66). The control group contained 40 healthy subjects (23 men and 17 women) with age 
of 19–56 (median age was 55). Blood samples were collected in the Department of 
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Physiology and Biochemistry, University of Physical Education in Wroclaw. Clinical and 
biochemical characteristics of the study group are reported in detail in Table 1.  
 
 
 
 
Healthy 
controls 
 
All 
patients 
 
Non-cirrhotic 
patients 
 
Cirrhotic 
patients 
(n) 40 129 41 88 
 
Male:Female ratio 
 
 
23:17 
 
68:61 
 
15:26 
 
53:35 
 
Age (years) 
 
 
55 
(19–56) 
 
66 
(18–74) 
 
56 
(18–69) 
 
55 
(21-74) 
Etiology (n) 
Virus hepatitis 
Alcohol 
Biliary 
  
62 
54 
13 
 
18 
21 
2 
 
44 
33 
11 
 
Albumin 
(g/L) 
 
45 
(36–57) 
 
34 
(16–45) 
 
37* 
(29–49) 
 
30* 
(16-45) 
 
ALT (U/L) 
 
24 
(20-28) 
 
40 
(16-79) 
 
28 
(24-33) 
 
47** 
(16-79) 
 
AST (U/L) 
 
27 
(23-30) 
 
70 
(19-150) 
 
41 
(19-64) 
 
79** 
(19-150) 
 
Bilirubin (mg/dL) 
 
0.7 
(0.6-0.9) 
 
0.98 
(1.0-3.6) 
 
0.92 
(0.90-0.95) 
 
1.6* 
(1.0-3.6) 
 
ǄGT (U/L) 
 
26 
(25.3-27.8) 
 
70 
(41-106) 
 
48 
(41-56) 
 
92** 
(78-106) 
 
AP (U/L) 
 
90 
(50-130) 
 
125 
(100-163) 
 
105 
(100-147) 
 
152** 
(141-163) 
 
Serum creatinine 
(mg/dL) 
 
0.8 
(0.7-1.0) 
 
1.4 
(0.7-2.4) 
 
0.96 
(0.9-1.2) 
 
1.39* 
(0.7-2.4) 
 
Serum sodium 
(mEq/L) 
 
140 
(138-141) 
 
137 
(129-142) 
 
136 
(129-138) 
 
130** 
(129-142) 
 
Table 1. Clinical and biochemical characteristics of the study subjects. Statistical significance: 
*P < 0.05; ** P < 0.01 vs. healthy controls. AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; AP, alkaline phosphatase; ǄGT, Ǆ-glutamyltransferase; INR, normalised 
international ratio; MELD, model of end-stage liver disease. 
www.intechopen.com
 
Oxidative Stress and Diseases 
 
362 
The diagnosis of liver cirrhosis was based on clinical, laboratory and ultrasonographic 
findings or histological criteria. Alcohol-related liver cirrhosis was diagnosed in 33 of 
patients, primary biliary cirrhosis in 11, cirrhosis caused by hepatitis C virus in 30, whereas 
cirrhosis caused by hepatitis B virus in 14 patients. The Child-Pugh score was used to assess 
the severity of liver disease. Three biochemical variables [serum albumin, bilirubin, and 
prothrombin time (international normalized ratio, INR)] in addition to the two clinical 
characteristics (presence or absence of ascites and clinical signs of encephalopathy) were 
determined. Patients were scored as follows: 5–6 as class (group) A, 7–9 as class (group) B 
and 10–15 as class (group) C. The patients with cirrhosis were divided into compensated 
(Child-Pugh class A) and decompensated (Child-Pugh classes B and C) groups. At the time 
of the study no Child-Pugh A patients showed clinical features of decompensated liver 
cirrhosis (ascites or hepatic encephalopathy). At enrollment, esophageal varices were 
detected by endoscopy in 88% of patients, ascites and hepatic encephalopathy grade were 
present by physical examination in 53 (60%) and 23 (26%) patients, respectively.   
Exclusion criteria were concurrent use of antioxidant drugs; co-existing diseases like 
diabetes mellitus, chronic kidney disease, cardiovascular disease, hepatocellular carcinoma; 
gastrointestinal bleeding, bacterial infection, and blood transfusion within previous two 
weeks. 
Patients had not been receiving diuretic, antibiotic, vasoactive drug (nitrates, ǃ-blockers), 
and lactulose or lactitiol therapy during the eight days before inclusion in the study. After 2 
h of bed rest, blood pressure was determined with an automatic digital sphygmomanometer 
and blood samples were collected in ice-cooled, ethylenediaminetetraacetic acid (EDTA)-
containing tubes for the determination of plasma renin activity, antidiuretic hormone, and 
plasma AOPPs or Nε-(carboxymethyl)lysine, in tubes with no additive for routine 
biochemical study and aldosterone and cytokine concentrations. All samples were separated 
immediately by centrifugation at 4°C and stored at -80°C until further analysis. 
The consent of the Bioethics Committee of the Wroclaw Medical University was obtained 
and all patients were informed about the character of analyses made. Studies were 
conducted in compliance with the ethical standards formulated in the Helsinki Declaration 
of 1975 (revised in 1983). 
2.2 Determination of circulating AOPPs 
In vivo plasma levels of AOPPs closely correlate with levels of dityrosine, a hallmark of 
oxidized proteins and with pentosidine, a marker of protein glycation closely related to 
oxidative stress. A new chromogen is found which caused increased absorbance at 340 nm 
and its spectrophotometric determination is proposed as a novel index of oxidative stress 
measuring the level of AOPPs (Witko-Sarsat et al., 1996). Two- hundred microliters of 
plasma diluted 1:5 in 20 mM phosphate buffer pH 7.4 containing 0.9% sodium chloride 
(PBS), or chloramine-T standard solutions (0 to 100 μmol/L), were placed in each well of a 
96-well microtiter plate (Becton Dickinson Labware, Lincoln Park, NJ, USA), followed by 20 
μL of 10% acetic acid. Ten microliters of 1.16 M potassium iodide (Sigma-Aldrich Co. LLC, 
Canada) were then added, followed by 20 μL of 10% acetic acid. The absorbance of the 
reaction mixture was immediately read at 340 nm in a microplate reader against a blank 
containing 200 μL of PBS, 10 μL of KI and 20 μL of 10% acetic acid. The chloramine-T 
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absorbance at 340 nm was linear within the range of 0 to 100 μmol/L. The ratio of AOPPs 
concentration to albumin level (AOPPs-albumin) was expressed in micromoles of AOPPs per 
gram of albumin (μmol/g). The ratio of AOPPs to albumin content allows the evaluation of 
whether the proportion of oxidatively modified albumin is altered. Coefficient of variation 
(CV) served as an indicator of precision. Intra-day and inter-day CV values were <10%. 
2.3 Determination of circulating Nε-(carboxymethyl) lysine 
Plasma Nε-(carboxymethyl)lysine (CML) levels were determined using a specific 
competitive ELISA kit [CircuLex CML/Nε-(carboxymethyl)lysine ELISA Kit (CycLex Co., 
Ltd, Nagano, Japan)]. Measurements were performed in duplicate and the results were 
averaged. The ratio of CML concentration to albumin level (CML-albumin) was expressed in 
micrograms of CML per gram of albumin (μg/g). 
2.4 Laboratory determinations 
Biochemical parameters were measured using routine laboratory methods. Serum high-
sensitivity C-reactive protein (hs-CRP) level was determined with a high-sensitivity 
nephelometric method using the Beckman Image Immunochemistry system (Beckman 
Instruments, Fullerton, CA), which has a minimum level of detection of 0.2 mg/L. Serum 
levels of TNF-ǂ and IL-6 were assayed with enzyme-linked immunosorbent assay (ELISA) kits 
(R&D Systems Inc., Minneapolis, MN, USA) according to the manufacturer’s instructions. The 
minimum levels of detection were 1.6 pg/mL and < 0.70 pg/mL for TNF-ǂ and IL-6, 
respectively. The intra- and interassay coefficients of variation for measurements of CRP, IL-6, 
and TNF-ǂ were 2.7%, 4.3%, and 5.0%, respectively, and 3.0%, 5.5, and 6.9%, respectively. 
Aldosterone (Aldoctk-2-P2714; Sorin Biomedica Diagnostics, Barcelona, Spain. Normal values, 
35-150 pg/mL) and plasma renin activity (Clinical Assays, Baxter, Cambridge, Mass., USA. 
Normal values, 0.4-2.3 ng mL-1 h-1) were measured by specific radioimmunoassays. 
Antidiuretic hormone was also tested by a commercial radioimmunoassay (Buhlman 
Laboratories, Basel, Switzerland. Normal values, less than 1 pg/mL). 
2.5 Measurement of the total antioxidant status of plasma 
The plasma antioxidant capacity was measured using a commercially available total 
antioxidant status TAS kit (Randox Laboratories, Crumlin, UK). The TAS assay is based on 
the inhibition by antioxidants of the absorbance of the radical cation of 2,2'-azinobis-(3-
ethylbenzothiazoline-6-sulfonate) (ABTS) formed by the interaction of ABTS with 
ferrylmyoglobin radical species. Upon the addition of a plasma sample, the oxidative 
reactions initiated by the hydroxyl radicals present in the reaction mix are suppressed by the 
antioxidant components of the plasma, preventing the color change and thereby providing 
an effective measure of the total antioxidant capacity of the plasma. The assay has excellent 
precision values, lower than 3%, and the results are expressed as mmol/L. 
2.6 Model for End-stage Liver Disease (MELD) score 
The model for end-stage liver disease (MELD) score was calculated from the following 
equation: 
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9.57 × loge (creatinine mg/dL) + 3.78 × loge (total bilirubin mg/dL) + 11.2 × loge 
(international normalized ratio-INR) + 6.43 (constant for liver disease etiology). 
The maximal creatinine concentration considered in the MELD score is 4.0 mg/dL (Huo et 
al., 2006). 
2.7 Statistical analysis 
Results are expressed as median (25th percentile–75th percentile). Frequency data were 
compared using the χ2 test or the Fischer’s exact test when necessary. Because many of the 
variables analyzed did not have a normal distribution as determined by the Kolmogorov-
Smirnov test, nonparametric tests were used for comparison of data. The Mann- Whitney U 
test and the Kruskal-Wallis test were used to analyze differences among two or more 
groups, respectively. Multivariate analysis by conditional logistical regression with a 
forward stepwise method was performed to find independent variables associated with the 
presence of ascites and low mean arterial pressure. Regression analysis to determine 
significant correlations among different parameters was performed using the Spearman 
correlation coefficient. Statistical significance was established at P < 0.05 
3. Results 
3.1 AOPPs-albumin plasma concentrations in patients with chronic liver disease and 
healthy controls 
We analyzed 129 patients (68 males/61 females, median age 66 years, range 18–74 years) 
with chronic liver disease. The distribution of the stages of liver cirrhosis as defined 
according to the Child–Pugh score, and measurements of AOPPs-albumin and CML-
albumin plasma concentrations are presented in Fig.1. The concentration of AOPPs-albumin  
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Fig. 1. (A) AOPPs-albumin serum concentrations in 129 patients with chronic liver disease, 
according to Child’s stage of cirrhosis, and in an control group of 40 healthy blood donors. P 
values are given in the table. Comparisons between subgroups are illustrated with box plot 
graphics, where the dotted line indicates the median per group, the box represents 50% of 
the values, and horizontal lines show minimum and maximum values of the calculated non-
outlier values; asterisks and open circles indicate outlier values. (B) AOPPs-albumin serum 
concentrations in patients with cirrhosis are correlated with the MELD (model of end-stage 
liver disease) score (r = 0.43, P < 0.01, Spearman rank correlation test). (C) CML-albumin 
serum concentrations increase with the stage of liver cirrhosis in patients with chronic liver 
disease. P values are given in the table. 
www.intechopen.com
 
Oxidative Stress and Diseases 
 
366 
in healthy subjects was 1.7 μmol/g (range 0.8-2.7 μmol/g, P < 0.05). In patients with chronic 
liver disease, AOPPs-albumin plasma concentrations were 1.3-fold higher. In healthy 
controls, the plasma AOPPs or CML were similar to those in control groups in other studies 
(Sebeková et al., 2002; Kalousová et al., 2003). 
3.2 AOPPs-albumin and liver cirrhosis 
AOPPs-albumin plasma concentration was significantly higher in patients with liver 
cirrhosis (n = 88, median 2.4 μmol/g, range 1.3-5.6 μmol/g) compared to patients with 
chronic liver disease without cirrhosis (n = 41, median 2.1 μmol/g, range 0.9-3.0 μmol/g) (P 
< 0.05, Fig.1A). Patients with Child-Pugh class C exhibited significantly higher plasma 
concentrations of AOPPs-albumin than patients with Child-Pugh class A and controls (P < 
0.05, P < 0.01, respectively) (Fig.1A). There was no significant difference in AOPPs 
concentrations between control subjects and Child-Pugh B cirrhotic patients.  
Differences in plasma AOPPs-albumin or CML-albumin were not significant in patients 
with liver cirrhosis of various etiologies (Table 2). Only in the group with primary biliary 
cirrhosis AOPPs-albumin were decreased (n = 11, median 1.3 μmol/g, range 0.80-2.2 
μmol/g), though it should be consider with caution since small number of subjects included 
in this group. 
 
  
AOPPs-albumin 
(μmol/g) 
 
CML-albumin 
(μg/g) 
 
TAS 
(mmol/L) 
 
Healthy controls 
(n=40) 
 
1.7 
(0.80-2.7) 
 
10.7 
(9.0–13.5) 
 
1.31 
(1.12-1.5) 
 
Viral hepatitis-related  
cirrhosis 
(n=44) 
 
3.09* 
(1.5-5.2) 
 
13.3* 
(11.6-18.1) 
 
0.65* 
(0.48-0.75) 
    
 
Alcohol-related cirrhosis 
(n=33) 
 
2.9* 
(1.6-4.3) 
 
16.3* 
(13.3-25.5) 
 
0.71* 
(0.60-0.73) 
 
Primary biliary 
cirrhosis 
(n=11) 
 
1.3 
(0.80-2.2) 
 
11.8 
(8.3-12.5) 
 
0.98 
(0.76-0.83) 
 
Biliary etiology shows lower AOPPs-albumin levels compared with other etiologies of liver disease. 
Significance levels between groups: *P < 0.05 vs. healthy controls. 
AOPPs, advanced oxidation protein products; CML, Nε-(carboxymethyl)lysine; TAS, total antioxidant 
status. 
Table 2. Plasma AOPPs-albumin, CML-albumin and TAS in liver cirrhosis patients of 
various etiologies. 
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The MELD scores were determined in the 88 patients with liver cirrhosis (Table 3). These were 
higher in the Child-Pugh C cirrhotic patients than in the Child-Pugh A cirrhotic patients 
(p<0.01). Significant correlations between AOPPs levels and MELD scores (r = 0.43, P < 0.01; 
Fig. 1B) were observed among the cirrhotic patients belonging to all three Child-Pugh classes. 
 
 
 
 
Healthy 
controls 
 
Non-cirrhotic 
patients 
 
Patients of 
class A 
 
Patients of 
class B 
 
Patients of 
class C 
 
(n) 
 
 
40 
 
41 
 
34 
 
34 
 
20 
 
Age (years) 
 
55 
(19–56) 
 
56 
(18–69) 
 
51 
(21–74) 
 
58 
(24–71) 
 
56 
(29–69) 
 
Albumin 
(g/L) 
 
45 
(36–57) 
 
40 
(29–49) 
 
34* 
(28–45) 
 
30* 
(20–40) 
 
25* 
(16–32) 
 
Bilirubin 
(mg/dL) 
 
0.7 
(0.6-0.9) 
 
0.92 
(0.90-0.95) 
 
1.01 
(1.02-1.03) 
 
1.56* 
(1.0-2.0) 
 
2.15* 
(1.1-3.6) 
 
AOPPs-albumin 
(μmol/g) 
 
1.7 
(0.8-2.7) 
 
2.1* 
(0.9-3.0) 
 
2.8* 
(1.3-4.4) 
 
3.2 
(1.9-4.5) 
 
4.1**+ 
(2.3–5.2) 
 
CML-albumin 
(μg/g) 
 
10.7 
(9.0–13.5) 
 
14.1 
(9.8-20.1) 
 
12.6* 
(8.3-18.2) 
 
15.8** 
(11.2–25.5) 
 
18.3** 
(9.7–23.8) 
 
Uric acid 
(mmol/L) 
 
0.35 
(0.25-0.39) 
 
0.29 
(0.21-0.33) 
 
0.31 
(0.26-0.34) 
 
0.22 
(0.16-0.24) 
 
0.18* 
(0.19-0.31) 
 
Vitamin C 
(µmol/L) 
 
54.3 
(38.3-70.3) 
 
45.2 
(31.9-58.6) 
 
47.1 
(28.3-64.0) 
 
33.6 
(20.2-45.7) 
 
36.9 
(29.2-54.2) 
 
TAS 
(mmol/L) 
 
1.3 
(1.1-1.5) 
 
1.1 
(0.9-1.3) 
 
0.9 
(0.6-1.0) 
 
0.63 
(0.5-0.76) 
 
0.53**+ 
(0.5-0.8) 
 
INR 
 
0.8-1.1 
 
- 
 
0.9 
(0.8-1.09) 
 
1.2 
(1.1-1.3) 
 
2.3 
(1.6-2.9) 
 
MELD score 
 
6-8 
-  
7.8 
(5.2-10.3) 
 
15.9* 
(8.7-23.1) 
 
24.1*+ + 
(14.4-28.4) 
 
Table 3. Plasma concentrations of AOPPs-albumin, CML-albumin and antioxidant 
parameters in patients with chronic liver disease without cirrhosis and in patients with 
cirrhosis. Significance between groups: *P < 0.05; ** P < 0.01 vs. healthy controls; + P < 0.05; 
++P < 0.01 vs. patients of class A. AOPPs, advanced oxidation protein products; CML, Nε-
(carboxymethyl)lysine; TAS, total antioxidant status; MELD, model for end-stage liver 
disease score. 
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3.3 CML-albumin plasma concentrations in patients with CLD and healthy controls 
In patients with chronic liver disease, CML-albumin had a median value of 14.1 μg/g (range 
9.8-20.1 μg/g). Plasma CML-albumin concentrations were higher in Child-Pugh A to C 
cirrhotic patients (n = 88, median 15.7 μg/g, range 8.3-25.5 μg/g) than in patients without 
cirrhosis, but this difference was not statistically significant (Fig. 1C). The levels of plasma 
CML-albumin in all liver cirrhotic patients were higher than those of the controls and this 
difference was statistically significant (Fig. 1C). Plasma CML-albumin in patients with 
Child-Pugh class C cirrhosis was only slightly elevated compared with those in Child-Pugh 
class A cirrhosis (P = 0.17) (Fig. 1C). There was no statistically significant correlation 
between CML-albumin levels and the Child-Pugh score in cirrhotic patients. 
3.4 Antioxidant parameters and liver cirrhosis 
As it is seen in Table 3, while all individual parameters of the antioxidant status tend to 
decrease, only the decrease of uric acid was statistically significant. There was a markedly 
decreased total antioxidant status (TAS) in patients with Child-Pugh class C cirrhosis 
compared to those with Child-Pugh class A cirrhosis or controls (P < 0.05, P < 0.01, 
respectively). Although differences between cirrhosis and chronic liver disease (n = 41, 
median 1.1, mmol/L, range 0.9-1.3 mmol/L) were not statistically significant, weak but 
significant correlation was observed between TAS and plasma AOPPs-albumin (r =-0.31, P < 
0.05). We failed to find, however, any relation between circulating CML-albumin levels and 
TAS (r = -0.22, P = 0.059). 
3.5 Markers of oxidative stress and hepatic function 
The serum albumin concentration was determined in all patients (n = 129, median 34 g/L, 
range 16–45 g/L) and healthy control subjects (n = 40, median 45 g/L, range 36–57 g/L). Level 
of albumin, the main substrate in both AOPPs and CML formation (Kalousová et al.; 2005), 
was significantly depleted both in chronic liver disease (n = 41, median 37 g/L, range 29–49 
g/L) and in cirrhosis (median 30 g/L, range 16-45 g/L) (Table 1). Plasma CML-albumin and 
foremost AOPPs-albumin showed significant associations with biochemical indices of liver 
function (albumin, prothrombin time, bilirubin concentration) but not with markers of liver 
injury – aminotransferases (Table 4). As expected, in patients with cirrhosis, AOPPs-albumin 
weakly but significantly correlated with the serum albumin (r = -0.38, P < 0.05). 
3.6 AOPPs-albumin, CML-albumin and chronic inflammatory state in cirrhotic patients 
We assessed the levels of several inflammatory markers and their association with the levels 
of AOPPs-albumin and CML-albumin. Serum high-sensitivity C-reactive protein (hs-CRP) 
levels and white blood cells (WBC) counts were significantly elevated in cirrhotic patients 
(Table 5). Serum TNF-ǂ levels were higher in the Child-Pugh class C cirrhosis patients than 
in the Child-Pugh class A cirrhosis patients (P < 0.05) (Table 5). Moreover, TNF-ǂ 
concentrations were weakly but significantly correlated with Child-Pugh score in cirrhotic 
group (r = 0.31, P < 0.05). The levels of serum IL-6 in cirrhotic patients were higher than 
those of the control group and this difference was statistically significant (P < 0.05) (Table 5). 
The levels of serum IL-6 in patients with Child-Pugh class C cirrhosis were higher than 
those in Child-Pugh class A cirrhosis, but this difference was not statistically significant. 
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AOPPs-albumin 
(μmol/g) 
 
CML-albumin 
(μg/g) 
 
Albumin (g/L) 
 
r = -0.38, P < 0.05 
 
r = - 0.26, P = 0.07 
 
ALT (U/L) 
 
r = 0.10, P = 0.54 
 
r = -0.14, P = 0.31 
 
AST (U/L) 
 
r = -0.20, P = 0.11 
 
r = -0.15, P = 0.26 
 
Bilirubin (mg/dL) 
 
r = 0.23, P = 0.07 
 
r = 0.24, P = 0.06 
 
Prothrombin ratio 
(%) 
 
r = -0.25, P < 0.05 
 
r = - 0.43, P < 0.001 
 
MELD score 
 
r = 0.43, P < 0.01 
 
r = 0.23, P = 0.07 
Table 4. Correlations between plasma AOPPs-albumin and CML-albumin and selected 
biochemical indices of liver function and injury. ALT, alanine aminotransferase; AST, 
aspartate aminotransferase; MELD, model for end-stage liver disease score. 
 
 
 
 
 
 
Healthy 
controls 
(n=40) 
 
Overall 
 
(n=88) 
 
Patients of 
class A 
(n=34) 
 
Patients of 
class B 
(n=34) 
 
Patients of 
class C 
(n=20) 
 
AOPPs-albumin 
(μmol/g) 
 
1.7 
(0.8-2.7) 
 
2.4* 
(1.3-5.6) 
 
2.8* 
(1.3-4.4) 
 
3.2 
(1.9-4.5) 
 
4.1*+ 
(2.3–5.2) 
 
CML-albumin 
(μg/g) 
 
10.7 
(9.0–13.5) 
 
15.7* 
(8.3-25.5) 
 
12.6* 
(8.3-18.2) 
 
15.8** 
(11.2–25.5) 
 
18.3** 
(9.7–23.8) 
 
Albumin 
(g/L) 
 
45 
(36–57) 
 
31** 
(16-35.4) 
 
34* 
(28–45) 
 
30* 
(20–40) 
 
25* 
(16–32) 
 
TNF-ǂ 
(pg/mL) 
 
32.9 
(31.0-35.2) 
 
41.5* 
(37.6-64.0) 
 
36.9* 
(37.7-45.6) 
 
42.0* 
(37.6-47.2) 
 
51.7*+ 
(48.7-58.3) 
 
IL-6 (pg/mL) 
 
5.9 
(5.4-6.8) 
 
13.3** 
(6.4-39.9) 
 
8.8* 
(6.4-34.6) 
 
12.3* 
(6.8-33.9) 
 
18.9* 
(9.0-39.9) 
 
hsCRP 
(mg/L) 
 
1.5 
(0.63-2.0) 
 
5.3** 
(4.9-11.0) 
 
4.8* 
(5.5-7.0) 
 
5.2** 
(4.9-7.7) 
 
6.3*+ 
(6.8-10.1) 
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Healthy 
controls 
(n=40) 
 
Overall 
 
(n=88) 
 
Patients of 
class A 
(n=34) 
 
Patients of 
class B 
(n=34) 
 
Patients of 
class C 
(n=20) 
WBC (x109/L) 4.0 
(4.2-5.0) 
5.0 
(1.1-8.6) 
4.7 
(1.1-8.6) 
5.2* 
(3.0-7.8) 
5.4**+ 
(2.7-8.2) 
 
MELD score 
 
6-8 
 
13.5* 
(5.2-28.4) 
 
7.8 
(5.2-10.3) 
 
15.9* 
(8.7-23.1) 
 
24.1*+ + 
(14.4-28.4) 
Table 5. Plasma concentrations of AOPPs-albumin, CML-albumin and inflammatory 
markers in healthy controls and in patients with liver cirrhosis. Significance levels between 
groups: *P < 0.05; ** P < 0.01 vs. healthy controls; + P < 0.05, ++P < 0.01 vs. patients of class A. 
AOPPs, advanced oxidation protein products; CML, Nε-(carboxymethyl)lysine; TNF, tumor 
necrosis factor; IL, interleukin; CRP, C-reactive protein; WBC, white blood cells; MELD, 
model for end-stage liver disease score. 
The association study revealed only a tendency toward an extremely weak but significant 
correlation between AOPPs-albumin and WBC in all cirrhotic patients (r = 0.23, P < 0.05). In 
turn, a weak but significant correlation between AOPPs-albumin levels and hs-CRP was 
observed among the cirrhotic patients belonging to all three Child-Pugh classes (r = 0.33, P < 
0.05). There was a significant correlation between the IL-6 and the AOPPs-albumin level (r = 
0.42, P < 0.05) and MELD score (r = 0.38, P < 0.05) in cirrhotic patients. As it was expected, a 
significant correlation between AOPPs-albumin levels and TNF-ǂ (r = 0.48, P < 0.05) was 
observed in Child-Pugh class A cirrhosis patients. In the multivariate analysis the 
relationship between plasma AOPPs-albumin, TNF-ǂ and Child-Pugh score was 
independent of age, sex and liver cirrhosis etiology (data not shown). 
There was no statistically significant correlation between CML-albumin level and hs-CRP or 
cytokines levels in all liver cirrhotic patients (data not shown).  
The ROC curve analyses are shown in Fig. 2 (sensitivity versus 1-specificity). The cut-off 
values of plasma AOPPs-albumin, TNF-ǂ and IL-6 to separate cirrhotic patients from 
healthy controls were 3.71 μmol/g, 37.2 pg/mL, and 8.95 pg/mL, respectively. 
3.7 Hemodynamic characteristics of the patients with liver cirrhosis 
Hemodynamic characteristics of patients are shown in Tables 1 and 6. Cirrhotic patients had 
significantly lower values of mean arterial pressure (MAP) when compared with controls 
(Table 6). Parameters related to hemodynamic disturbances such as decreased mean arterial 
pressure and increased plasma renin activity and aldosterone levels deteriorated with 
increasing of Child-Pugh score. However, similar values of antidiuretic hormone were 
detected in all patients grouped according to the Child-Pugh classification.  
Among clinical parameters of liver dysfunction ascites revealed significant association with 
plasma AOPPs-albumin, TNF-ǂ and IL-6 (Table 6). By contrast, patients presented similar 
AOPPs-albumin levels when classified according to the presence or absence of 
encephalopathy grade I (data not shown). Ascitic patients had a more intense alteration of 
hemodynamic parameters (plasma renin activity, aldosterone), along with higher levels of  
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Fig. 2. Receiver operating characteristic (ROC) curve and optimal cut-off levels of advanced 
oxidation protein products (AOPPs), tumor necrosis factor-ǂ (TNF-ǂ), and interleukin-6 (IL-
6) for distinguishing cirrhotic patients from healthy controls; AUC, area under the curve. 
AOPPs-albumin, TNF-a, and IL-6, compared with patients without ascites. Cirrhotic 
patients who had ascites showed higher AOPPs-albumin levels (n = 53, median 3.6 μmol/g, 
range 1.5-5.3 μmol/g) than patients without ascites (n = 35, median 2.2 μmol/g, range 1.0-
3.4 μmol/g) (P < 0.05, Table 6). AOPPs-albumin levels were not different between cirrhotic 
patients without ascites and controls, while patients with ascites had higher AOPPs-albumin 
levels than controls (median 1.7 μmol/g, range 0.8-2.7 μmol/g) (P < 0.01). High IL-6 levels 
showed an independent association with the presence of ascites. 
To differentiate cirrhotic patients with a more intense hemodynamic alteration 
(vasodilatation), we divided patients according to those with low mean arterial pressure 
(MAP ≤83 mm Hg) and high mean arterial pressure (MAP >83 mm Hg) (Table 7). Only IL-6 
levels were significantly higher in patients with more severe vasodilatation; this association 
was independent of other factors. 
Plasma levels of AOPPs-albumin very weakly but significantly correlated with MAP (r = -
0.25, P < 0.01; Fig.3). Furthermore, IL-6 levels had a significant correlation with several 
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parameters, including plasma renin activity (r = 0.39, P < 0.05) and MAP (r = -0.38, P < 0.01), 
in addition to albumin (r = - 0.51, P < 0.001). Neither TNF-ǂ levels nor the CML-albumin 
levels correlated significantly with hemodynamic parameters. 
 
  
Overall 
 
 
(n=88) 
 
 
Patients 
of class A 
 
(n=34) 
 
 
Patients of 
class B 
 
(n=34) 
 
 
Patients 
of class C 
 
(n=20) 
 
 
Cirrhosis 
without 
ascites 
(n=35) 
 
 
Cirrhosis 
with 
ascites 
n=53) 
 
 
Mean arterial 
pressure- 
MAP 
(mmHg) 
 
83 
(76-93) 
 
89 
(85-93) 
 
83 
(77-91) 
 
76* 
(73-81)  
 
88 
(85-93) 
 
77+ 
(73-89) 
 
Plasma 
renin 
activity  
 (ng mL-1 h-1) 
 
0.6 
(0.1-7.6) 
 
0.37 
(0.1-1.2) 
 
1.9* 
(0.95-4.8)  
 
6.0** 
1.2-7.6)  
 
0.48 
(0.13-1.6) 
 
1.9++ 
(0.51-6.2) 
 
Aldosterone 
(ng/dL) 
20.6 
(14.0-51.0) 
 
15.0 
(5.0-71.0) 
 
12.0 
(5.0-19.0) 
 
20.6 
(14.0-/51.0) 
 
30.0* 
(21.0-71.0) 
 
13.2 
(5.5-20.9) 
 
33.0+++ 
(13.7-
52.2) 
 
Antidiuretic 
hormone 
(pg/mL) 
 
4.9 
(2.5-6.5) 
 
3.8 
(2.5-5.7) 
 
4.5 
(3.7-6.2) 
 
4.8 
(3.8-6.5) 
 
4.6 
(3.0-6.8) 
 
4.5 
(3.6-6.4) 
 
 
AOPPs-
albumin 
(μmol/g) 
 
2.4 
(1.3-5.2) 
 
2.8 
(1.3-4.4) 
 
3.2 
(1.9-4.5) 
 
4.1* 
(2.3–5.2)  
 
2.2 
(1.0-3.4) 
 
3.6+ 
(1.5-5.3) 
 
TNF-ǂ 
(pg/mL) 
 
41.5 
(37.6-64.0) 
 
36.9 
(37.7-45.6) 
 
42.0 
(37.6-47.2) 
 
51.7* 
(48.7-58.3) 
 
37.5 
(35.4-46.5) 
 
57.5+ 
(52.1-69.7) 
 
IL-6 
(pg/mL) 
 
13.3 
(6.4-39.9) 
 
8.8 
(6.4-34.6) 
 
12.3 
(6.8-33.9) 
 
18.9 
(9.0-39.9 
 
6.4  
(5.6-7.3) 
 
10.8++ 
(8.5-12.4) 
 
 Significance between groups: *P < 0.05; **P < 0.001 vs. patients of class A. +P < 0.05; ++P < 0.01, +++P < 
0.001 vs. liver cirrhosis without ascites. AOPPs, advanced oxidation protein products; TNF, tumor 
necrosis factor; IL, interleukin. 
Table 6. Blood pressure, plasma renin activity and plasma concentrations of aldosterone, 
antidiuretic hormone and AOPPs-albumin according to the Child–Pugh class or presence of 
ascites. 
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Mean arterial pressure 
(MAP) ≤ 83 mm Hg 
(n=51) 
 
Mean arterial pressure 
(MAP) > 83 mm Hg 
(n=37) 
 
Plasma renin activity  
 (ng mL-1 h-1) 
 
1.7 
(0.46-5.5) 
 
1.4 
(0.37-4.4) 
 
Aldosterone 
(ng/dL) 
 
25.6 
(10.6-40.5) 
 
13.7 
(5.7-21.6) 
 
Antidiuretic hormone 
(pg/mL) 
 
4.7 
(3.7-6.7) 
 
4.2 
(3.3-5.9) 
 
AOPPs-albumin 
(μmol/g) 
 
3.3 
(1.4-4.8) 
 
3.01 
(1.2-4.5) 
 
IL-6  
(pg/mL) 
 
11.0+ 
(9.5-12.8) 
 
6.3 
(5.4-7.0) 
 
TNF-ǂ  
(pg/mL) 
 
47.9 
(43.4-58.0) 
 
49.8 
(45.1-60.3) 
Table 7. Comparison between cirrhotic patients classified according to the finding of low (≤ 
83 mm Hg) and high (>83 mm Hg) mean arterial pressure (MAP). Significance between 
groups: +P < 0.01 by multivariate analysis. 
 
Fig. 3. AOPPs-albumin concentrations are very weakly but significantly correlated with the 
mean arterial pressure (MAP) in patients with chronic liver disease (r = -0.25, P < 0.01). 
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4. Discussion 
Cirrhosis is characterized by inflammation of the liver, often caused by a rise in oxygen-
derived free radicals within the liver. Under normal circumstances, the liver maintains a 
supply of internal antioxidants to neutralize the reactive species generated in response to 
viral infection and during metabolism of various endo- and exogenous compounds 
processed in the liver. However, when the liver antioxidants are low, or when the liver is 
undergone to continued oxidative insults (e.g., long-lasting alcohol abuse or infection with 
different hepatitis viruses), the damage from reactive species (Halliwell, 2007) may increase, 
resulting in inflammation and the formation of scar tissue (fibrosis) (Valko et al., 2007). The 
progressive decrease of antioxidant reserves, the dysfunction of liver microcirculation 
through nitric oxide-mediated pathways, may determine the shift to liver cirrhosis. 
Advanced glycation and oxidation endproducts (AGEs and AOPPs, respectively) cause 
oxidative stress and trigger cytokine driven inflammatory reactions in vitro. (reviewed in 
Yan et al., 2010). The net effects on markers of inflammation and hemodynamic changes in 
cirrhotic patients are unknown. 
Advanced glycation endproducts are formed from the reaction of glucose and other 
reducing sugars with amino acid groups of proteins. This interaction generates a labile 
Schiff base followed by rearrangement to more stable Amadori-products, and subsequently 
these early glycation products may undergo further chemical rearrangements resulting in 
various irreversibly formed AGEs (Baynes & Thorpe, 1999). Three different mechanisms 
have been proposed by which AGEs lead to cirrhosis complications: 1) the binding of AGEs 
to the receptors for advanced glycation endproducts on different cell types including 
monocytes/macrophages, T lymphocytes, endothelial cells, smooth muscle cells, and 
activation of cell signaling pathways with subsequent modulation of gene expression, 2) 
intracellular AGEs formation leading to impaired cell function, and 3) the accumulation of 
AGEs in the extracellular matrix. CML-albumin levels (as prototype of the AGEs) were 
higher in cirrhosis groups than in the controls. In agreement with two previous reports 
(Zuwala-Jagiello et al., 2009; 2011) these results indicate that reactive oxygen species are 
overproduced in patients with liver cirrhosis. CML may lead to progression of cirrhosis by 
interaction with receptors that induce production of reactive species followed by a release of 
inflammatory cytokines in different cell types (Bierhaus et al., 1998; Raj et al., 2000) such as 
IL-6, ultimately leading to the production of CRP by the liver. A correlation to high sensitive 
C-reactive protein (hs-CRP) could not be demonstrated, and the suggestion that high levels 
of CML may activate an inflammatory response was not demonstrated by serum markers 
(TNF-ǂ and IL-6). It is likely that the blood load of CML resembles only a small fraction of 
body’s AGEs content and that the serum levels reflect particular changes in the body’s AGEs 
pool. Thus, circulating CML-albumin may not be an adequate parameter for demonstrating 
effects on inflammatory response in cirrhotic patients. Most likely the focus should be on 
intracellular AGEs (Thornalley et al., 2003). 
A role of oxidative stress in the pathogenesis of chronic liver disease has been proposed by 
several authors (Bandara et al., 2005; Nagata et al., 2007; Nakhjavani et al., 2011; Serejo et al., 
2003; Zuwala-Jagiello et al., 2007). Studies have shown increased plasma levels of markers of 
lipid peroxidation and reduced plasma antioxidant content. Protein oxidation products are 
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increasingly being used as markers instead of lipid peroxidation products in 
demonstrating oxidative stress (Dalle-Donne et al., 2003). AOPPs measurements reflect the 
reactive species generation and the degree of protein oxidation (Witko-Sarsat et al., 1996). 
It was reported that AOPPs generated by different oxidation patterns lead to the 
production of either hydrogen peroxide or nitric oxide (Servettaz et al., 2007). Nitric oxide 
can interact with superoxide anion-radical forming reactive nitrogen species such as 
peroxynitrite. These reactive nitrogen species secondarily promote important reactions 
such as nitrosation, oxidation or nitration, leading to impaired cellular functions and 
enhanced inflammatory reactions (Friedman, 2008; Iwakiri & Groszmann, 2007). AOPPs 
are referred to as markers of oxidative stress as well as markers of neutrophil activation in 
chronic disease (Witko-Sarsat et al., 2003). It has thus been shown that chlorinated 
oxidants of neutrophil origin may lead to oxidative stress, notably protein oxidation. Once 
formed, such AOPPs foci create a nidus for the amplification of oxidative stress. In 
addition to increased formation, decreased removal/detoxification of AOPPs may 
contribute to the stress. There is increasing evidence that the liver plays important roles in 
the elimination of AOPPs (Iwao et al., 2006). In patients with chronic liver diseases, 
constriction of the sinusoidal blood stream leads to the development of portal 
hypertension with portocaval shunts (Svistounov & Smedsrød, 2004). The hindrance of 
substance exchange between hepatocytes and the sinusoidal blood stream could increase 
plasma level of AOPPs in these patients. Therefore, the liver, especially in cirrhotic 
patients, cannot prevent the accumulation of AOPPs effectively. Finally, our findings 
extended the results of Oettl et al. (2008) which suggested that albumin is oxidatively 
modified in patients with advanced liver disease depending on its severity. The present 
finding that AOPPs-albumin accumulation coexists with decreased TAS, while the plasma 
concentration of CML-modified albumin remains stable, supports the contention that 
AOPPs-albumin is more accurate marker of oxidative stress than glycoxidation products 
in cirrhotic patients. An increase in reactive species formation, manifested by increased 
hepatic and plasma levels of AOPPs (Gorka et al., 2008; Sebeková et al., 2002; Yagmur et 
al., 2006; Zuwala−Jagiello et al., 2006;) and as well as decreased antioxidant levels (Jain et 
al., 2002; Zuwala−Jagiello et al., 2009) have been reported in patients with liver cirrhosis. 
Finally, our previous study found that the patients with cirrhosis were exposed to 
oxidative stress and the level of AOPPs was significantly related to the severity of liver 
cirrhosis of various etiologies (Zuwala-Jagiello et al., 2011).  
The adverse effects of oxidative stress on the progression of cirrhosis may be categorized 
into effects on protein modifications and inflammatory response. Figure 4 presents a 
summary of the effects of AOPPs or AGEs and oxidative stress on markers of inflammation 
and hemodynamic changes in cirrhotic patients. 
Very recently, advanced glycation endproducts have been found to act as pro-inflammatory 
factors (Sparvero et al., 2009). Nevertheless, AOPPs are believed to be more closely related to 
inflammation (Fialova et al., 2006) than AGEs, whose RAGE participates in AOPPs-mediated 
signal transduction (Kalousová et al., 2005; 2006). These interactions enhance reactive 
oxygen species formation, with activation of nuclear factor NF-κB and release of pro-
inflammatory cytokines (Bierhaus et al., 2006; Hyogo & Yamagishi, 2008; Saito & Ishii, 2004) 
(Fig. 4). Moreover, the macrophage RAGE can be up-regulated by TNF-ǂ (Miyata et al., 
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1994). This is accompanied by the activation of macrophages and increased expression of 
TNF-ǂ (Giron-González et al., 2004). TNF-ǂ production is also stimulated by macrophage 
sensing of intestinal microflora pathogen associated molecular patterns by toll-like receptors 
(Riordan et al., 2003). It could therefore be consistent with observed increase levels of both 
AOPPs-albumin and TNF-ǂ at an early stage of liver cirrhosis.  
The hyperdynamic circulatory state associated with liver cirrhosis is characterized by 
vasodilatation and increased cardiac output; the arterial hypotension and relative 
hypovolemia caused by vasodilatation activate a number of vasoactive and neurohumoral 
systems (Wiest & Groszmann, 2002). TNF-ǂ induces an endothelial activation, which can be 
detected by increased synthesis of nitric oxide (Spitzer, 1994). Endogenous nitric oxide, a 
powerful endothelium-derived vasodilator, has been implicated in hemodynamic changes 
present in cirrhotic patients (Garcı’a-Tsao et al., 1998). Treatment with both specific anti-TNF 
polyclonal antibodies and thalidomide, an inhibitor of TNF-ǂ production, significantly 
prevent the development of the hyperdynamic circulation and reduces portal pressure 
(Gatta et al., 2008). TNF-ǂ levels in our patients were clearly different from control group 
and were much higher in ascitic patients. However, no differences existed between patients 
with high and low mean arterial pressure, and no significant correlations with 
hemodynamic values were found. These data suggest that, although TNF-ǂ might be one of 
the inducers of nitric oxide generation in cirrhotic patients, other factors acting through 
different pathways probably exist.  
AOPPs derived from in vivo sources stimulated endothelial cell generation of reactive 
oxygen species, in particular superoxide anion (Guo et al., 2008), at least in part through 
NADPH-oxidase (Wautier et al., 2001). However, the exact mechanisms and sources by 
which reactive oxygen species are generated in the vasculature are not yet known in detail. 
It has been observed in several experimental animal models, that the endothelium is one of 
the major sources for the generation of reactive oxygen species. In parallel with the vascular 
dysfunction the formation of superoxide anions became augmented, and removal of 
endothelium completely abolished the production of reactive oxygen species. (reviewed in 
Wright et al., 2006). In another report, Rhee et al. (2003) demonstrated that growth factor-
induced H2O2 production (e.g. PDGF, EGF) requires the activation of phosphoinositide 3-
kinase. The essential role of phosphoinositide 3-kinase is likely to provide 
phosphatidylinositol (3, 4, 5)-trisphosphate that recruits and activates a guanine nucleotide 
exchange factor of Rac, which is required for the activation of NADPH-oxidase. Thus, the 
generation of reactive oxygen species is largely dependent on the activation of NADPH-
oxidase that is present in endothelial cell. AOPPs stimulated endothelial cell activation of 
the following signaling mediators: NADPH oxidase and NF-κB, the factors linked to 
increased expression of pro-inflammatory adhesion molecules, such as intercellular 
adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1) (Kim et al., 
2001; Yan et al., 2010) (Fig. 4). Endothelial activation plays an active role in the modifications 
of circulatory status of cirrhotic patients (Grangé & Amiot, 2004). Elevated levels of AOPPs-
albumin were detected in the early stages of liver dysfunction: plasma concentrations were 
increased in patients in Child Pugh class A, with higher values found in those in class B or 
C. Plasma concentrations of AOPPs-albumin were very weakly correlated with 
hemodynamic alterations (mean arterial pressure).  
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Fig. 4. Summary of the effects of AOPPs or AGEs and oxidative stress on markers of 
inflammation and hemodynamic changes in cirrhotic patients. AOPPs or AGEs bind with 
RAGE on the surface of endothelial cells lining blood vessels. AOPPS, AGEs ligands of 
RAGE sustain stimulation of RAGE. One consequence of RAGE signaling is the activation of 
NADPH oxidase and production of reactive oxygen species. Once formed, reactive oxygen 
species activate key transcription factor such as NF-κB, which results in the transcriptional 
activation of genes relevant for inflammation. Consequences include increased migration 
and activation of RAGE-expressing macrophages. This results in release of the pro-
inflammatory cytokines. In this inflammatory environment, via interaction with RAGE on 
the surface of macrophages, AOPPs or AGEs magnify activation of NF-κB and other factors, 
thereby amplifying cellular stress and hepatic damage. In the aggregate, these processes 
may contribute to propagation of inflammation and vascular perturbation in liver cirrhosis. 
AGEs, advanced glycation endproducts; AOPPs, advanced oxidation protein products; CRP, 
C-reactive protein; ICAM-1, intercellular adhesion molecule 1; IL, interleukin; MAP, 
mitogen activated protein; NADPH, nicotinamide adenine dinucleotide phosphate (reduced 
form); NF-κB, nuclear factor κB; RAGE, receptor for AGEs; ROS, reactive oxygen species; 
TNF-ǂ, tumour necrosis factor ǂ; VCAM-1, vascular cell adhesion molecule. 
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These results suggested that this association of AOPPs with hemodynamic disturbances is 
dependent of the severity of cirrhosis. Additionally, AOPPs levels could be elevated as a 
result of insufficient renal elimination. However, the precise mechanism by which AOPPs is 
cleared from plasma is currently unknown. In addition, we found no correlation between 
AOPPs-albumin and serum creatinine levels. In any case, the values of AOPPs-albumin in 
patients with a low Child-Pugh score and absence of ascites suggests that AOPPs might 
have a role in the late stages of cirrhosis by aggravating the already initiated vasodilatation. 
Indeed, the presence of ascites, one of the major complications of cirrhosis and closely 
related to the hemodynamic disturbances of cirrhotic patients, was found in patients with 
higher levels of AOPPs. Finally, the extremely weak correlation between AOPPs-albumin 
levels and mean arterial pressure may suggest an indirect contribution of AOPPs to arterial 
vasodilatation through other mediators. 
Structure and function of albumin are impaired in advanced liver disease by different 
mechanisms: plasma levels are decreased due to reduced synthesis and albumin is 
oxidatively modified. In this context, AOPPs-albumin may shows altered binding capacities 
for several substances. Decreased bilirubin binding was reported for in vitro oxidized 
albumin (Oettl & Stauber, 2007). As bilirubin is preferentially bound by the fully reduced 
form of albumin, impaired binding of bilirubin and other ligands (e.g. nitric oxide) is likely 
to occur in liver cirrhosis. Theoretically, increased circulating AOPPs-albumin may 
indirectly lead to elevation of nitric oxide which can, in turn, contribute to oxidative stress in 
cells (La Villa & Gentilini, 2008). Finally, nitric oxide plays a major key role in the 
development of hyperdynamic circulation and portal hypertension in cirrhosis (Iwakiri & 
Groszmann, 2007). Infusion of albumin (Garcovich et al., 2009) as well as albumin dialysis 
has been shown to improve the circulatory dysfunction as evidenced by an increase in mean 
blood pressure and systemic vascular resistance (Mitzner et al., 2001). This improvement in 
systemic hemodynamics might be due to a reduction in vasodilation following removal of 
nitric oxide which results in deactivation of the neurohormonal systems and a decrease in 
plasma levels of renin, aldosterone, norepinephrine and vasopressin (Chen et al., 2009). 
However, other findings of the present study imply that AOPPs are not only the factors 
responsible for the hemodynamic changes observed in cirrhotic patients. The AOPPs-
albumin levels did not correlate significantly with the parameters that accompany important 
hemodynamic alterations in cirrhotic patients, such as plasma renin activity and 
aldosterone. Finally, when cirrhotic patients in our study were divided according to high 
and low mean arterial pressure, we found similar AOPPs-albumin levels in both groups.  
Portal hypertension and cirrhosis can increase gut permeability to endotoxin and impair 
reticuloendothelial function of the liver that may result in increased serum endotoxin 
concentrations (Cariello et al., 2010). This may be a stimulus for the production of pro-
inflammatory cytokines, resulting in the increased production of acute phase proteins such 
as C-reactive protein. In turn, CRP is capable of stimulating IL-6 and TNF-ǂ production by 
monocytes (Ballou & Lozanski, 1992) and reactive oxygen species formation (Wang et al., 
2003). Advanced oxidation protein products, as pro-inflammatory factors, accumulated in 
cirrhotic patients (Zuwala−Jagiello et al., 2006, 2009, 2011) and played an important role in 
the occurrence and progression of complications such as dysfunction of endothelial cells 
(Witko-Sarsat et al., 1998). AOPPs correlate well with certain cytokines (Kalousová et al., 
2005) as well as with some markers of inflammation, including fibrinogen, orosomucoid. 
Even if the correlation between AOPPs-albumin and hs-CRP were poor, other studies 
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demonstrated fair associations with other markers of oxidative stress, such as lipid 
peroxidation products and F2-isoprostanes. Furthermore, results from a recent study 
demonstrate that glycosylated and oxidized proteins indirectly up-regulate CRP expression 
in hepatocytes by stimulating monocytes to produce IL-6 (Li et al., 2007). It seem, based on 
our study, even though there was functional loss of hepatocytes in patients with hepatic 
cirrhosis, the serum CRP level was still maintained in high level and dependent of AOPPs-
albumin level with its significant correlation. The remaining viable hepatocytes may still 
contribute to this result. IL-6 is the main stimulant for hepatic production of CRP but also 
has other important roles leading to increased endothelial cell adhesiveness by up-
regulating ICAM-1, and VCAM-1 and releasing inflammatory mediators, including IL-6 
itself (Szmitko et al., 2003). Finally, the significant correlation between the levels of AOPPs 
and IL-6 supports the existence of a link between AOPPs and hemodynamic changes 
present in cirrhotic patients (Fig. 4). 
Portal hypertension is characterized by intrahepatic vascular resistance causing an increase 
of portal vein pressure, and leads to the development of ascite (Møller et al., 2008). IL-6 
levels in our cirrhotic patients were different from those in controls, increased with the 
severity of liver disease, were independently associated to the presence of ascites. IL-6 
increased in serum of patients with ascites compared to compensated (Child-Pugh class A) 
patients without ascites, and similar results were obtained in a study where serum IL-6 was 
also analyzed (Zhang et al., 2002). In a simplistic view, portal hypertension leads to the 
formation of portosystemic collateral veins in liver cirrhosis and the resulting shunting 
(Cichoz-Lach et al., 2008) also contributes to impaired hepatic uptake of IL-6. It has been 
convincingly shown that hepatic uptake of IL-6 is significantly impaired in patients with 
liver cirrhosis, and this may at least in part explain elevated serum levels in these patients 
(Soresi et al., 2006). In our study, IL-6 levels increase significantly in association with the 
severity of liver cirrhosis according to the MELD score. Moreover, IL-6 levels in all cirrhotic 
patients were independently associated to the presence of low mean arterial pressure, and 
showed significant correlations with parameters related to hemodynamic abnormalities. The 
mechanism by which IL-6 could cause vasodilatation is unknown. However, the effect 
appears to be independent of nitric oxide, possibly due to an important role of prostacyclin 
synthesis (Dagher & Moore, 2001). It is then possible that IL-6 would produces 
vasodilatation by inducing prostacyclin synthesis; the effect of IL-6 would be potentiated by 
AOPPs stimulation (Li et al., 2007).  
Further, investigators have tried to find more noninvasive biomarkers for cirrhotic patients 
for years (Schuppan & Afdhal, 2008). We observed good abilities of plasma AOPPs-albumin, 
TNF-ǂ and IL-6 levels to distinguish cirrhotic patients from healthy controls, with good 
sensitivities and specificities by ROC analysis. Additionally, these parameters also were 
found to be elevated in concordance with the severity of cirrhosis. Thereby, it is possible that 
plasma levels of AOPPs-albumin, TNF-ǂ and IL-6 levels could be evaluated as candidate 
biomarkers for initial and long-term assessment of liver cirrhosis. 
5. Conclusion 
In conclusion, there are differences between advanced oxidation protein products modified–
albumin (AOPPs-albumin), which act as a pure oxidative stress marker, and Nε 
(carboxymethyl)lysine modified-albumin (CML-albumin; as prototype of the advanced 
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glycation endproducts-AGEs), which behave as both oxidative and carbonyl stress markers. 
AOPPs-albumin shows a closer relationship to inflammation than CML-albumin. Because of 
the relationship of AOPPs-albumin with formation of inflammation, their relationship with 
certain inflammatory markers and their changes during progression of chronic liver disease, 
AOPPs may provide a marker of chronic long-lasting liver damage. Oxidative stress not 
only contributes to the derangement of hemodynamic chronic liver failure, but also 
gradually increases with its progression to end-stage liver disease. 
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